FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555412546> ?p ?o ?g. }

• W2555412546 abstract "Abstract Hydroxamic acid analogue pan-histone deacetylase (HDAC) inhibitors (HA-HDIs), e.g., vorinostat, LAQ824 and LBH589, induce in vitro growth arrest, differentiation and apoptosis of human acute leukemia cells. Continuous and protracted use of HA-HDI, as currently used in the clinic against hematologic malignancies is likely to result in the emergence of HA-HDI resistance in leukemia cells. By continuous in vitro exposure of the AML HL-60 cells to the cinnamic acid analogue HA-HDI LAQ824, we have generated an in vitro and in vivo model of HA-HDI-resistant HL-60/LR cells, which are capable of growth in high concentrations (200 nM) of LAQ824. HL-60/LR versus the parental HL-60 cells have a shorter doubling time (12 versus 24 hours), increased % of cells in the S phase of the cell cycle (62.4 versus 40.0) and exhibit shorter interval to generation of leukemia and survival in NOD/SCID mice. As compared to HL-60, HL-60/LR cells have a resistance index of 100 for LAQ824, and are cross-resistant to other antileukemia agents exhibiting resistance index for LBH589: 50; trichostatin A: 15; vorinostat: 30; sodium butyrate: 10; etoposide: 5.0; Ara-C: 3.3 and TRAIL: 31.3. As compared to HL-60, HL-60/LR cells express higher levels of Bcl-xL and XIAP but lower levels of MCL-1. HL-60/LR versus HL-60 cells also express markedly reduced levels of Bim and Bak but higher levels of Bax. Although expressing higher levels of the death receptors (DR) 4 and 5 and lower levels of c-FLIP, HL-60/LR cells lack expression of caspase-8 and show barely detectable levels of FADD. Additionally, HL-60/LR versus HL-60 cells have markedly higher levels of AKT, c-RAF, and p-STAT5. Although expressing higher levels of HDAC1, HDAC2, and HDAC4, HL-60/LR cells lack detectable expression of HDAC6, with increased expression of hyper-acetylated hsp90 and α-tubulin- two of the substrates deacetylated by HDAC6. As compared to hsp90 in HL-60 cells, hyper-acetylated hsp90 in HL-60/LR cells exhibits less binding to ATP and p23. Utilizing a polyclonal antibody generated against acetylated hsp90α, confocal immunofluorescence microscopy showed higher and mostly cell surface expression of acetylated hsp90α in HL-60/LR versus HL-60 cells. As compared to HL-60, treatment of HL-60/LR cells with LAQ824 failed to induce p21 and hsp70, or increase the levels of hyper-acetylated hsp90 and α-tubulin. Notably, although cross-resistant to several anti-leukemia drugs, HL-60/LR cells are collaterally sensitive to the hsp90-inhibiting geldanamycin analogues 17-allylamino-demothoxy geldanamycin (17-AAG) and 17-DMAG with a four and five-fold increased sensitivity to 17-AAG and 17-DMAG, respectively. This was associated with a lack of both a 17-AAG mediated induction of hsp70 and a lesser decline in the levels of AKT and c-RAF in HL-60/LR versus HL-60 cells. Taken together, these findings elucidate several notable in vitro and in vivo biologic characteristics and drug-sensitivity profile of the first fully-characterized HA-HDI-resistant human AML cells. Our findings clearly demonstrate that in vitro resistance to HA-HDIs is associated with loss of HDAC6 expression, hyperacetylation of hsp90, aggressive leukemia phenotype, but cross-sensitivity to 17-AAG. These findings also suggest that hsp90 inhibitors should be tested for overriding de novo or acquired HA-HDI resistance in AML." @default.
• W2555412546 created "2016-11-30" @default.
• W2555412546 creator A5000407889 @default.
• W2555412546 creator A5010724567 @default.
• W2555412546 creator A5017662665 @default.
• W2555412546 creator A5020383322 @default.
• W2555412546 creator A5029250422 @default.
• W2555412546 creator A5043075583 @default.
• W2555412546 creator A5044723679 @default.
• W2555412546 creator A5049376902 @default.
• W2555412546 creator A5067678169 @default.
• W2555412546 creator A5077507982 @default.
• W2555412546 creator A5079069209 @default.
• W2555412546 date "2007-11-16" @default.
• W2555412546 modified "2023-09-27" @default.
• W2555412546 title "Molecular Characterization and Drug-Sensitivity of Pan Histone Deacetylase Inhibitor Resistant Human Acute Myeloid Leukemia Cells." @default.
• W2555412546 doi "https://doi.org/10.1182/blood.v110.11.807.807" @default.
• W2555412546 hasPublicationYear "2007" @default.
• W2555412546 type Work @default.
• W2555412546 sameAs 2555412546 @default.
• W2555412546 citedByCount "1" @default.
• W2555412546 crossrefType "journal-article" @default.
• W2555412546 hasAuthorship W2555412546A5000407889 @default.
• W2555412546 hasAuthorship W2555412546A5010724567 @default.
• W2555412546 hasAuthorship W2555412546A5017662665 @default.
• W2555412546 hasAuthorship W2555412546A5020383322 @default.
• W2555412546 hasAuthorship W2555412546A5029250422 @default.
• W2555412546 hasAuthorship W2555412546A5043075583 @default.
• W2555412546 hasAuthorship W2555412546A5044723679 @default.
• W2555412546 hasAuthorship W2555412546A5049376902 @default.
• W2555412546 hasAuthorship W2555412546A5067678169 @default.
• W2555412546 hasAuthorship W2555412546A5077507982 @default.
• W2555412546 hasAuthorship W2555412546A5079069209 @default.
• W2555412546 hasConcept C104317684 @default.
• W2555412546 hasConcept C203014093 @default.
• W2555412546 hasConcept C2776202225 @default.
• W2555412546 hasConcept C2776262904 @default.
• W2555412546 hasConcept C2777865847 @default.
• W2555412546 hasConcept C2778305200 @default.
• W2555412546 hasConcept C2778461978 @default.
• W2555412546 hasConcept C2778729363 @default.
• W2555412546 hasConcept C2778942008 @default.
• W2555412546 hasConcept C2780225316 @default.
• W2555412546 hasConcept C502942594 @default.
• W2555412546 hasConcept C54355233 @default.
• W2555412546 hasConcept C55493867 @default.
• W2555412546 hasConcept C64927066 @default.
• W2555412546 hasConcept C81885089 @default.
• W2555412546 hasConcept C86803240 @default.
• W2555412546 hasConcept C98274493 @default.
• W2555412546 hasConceptScore W2555412546C104317684 @default.
• W2555412546 hasConceptScore W2555412546C203014093 @default.
• W2555412546 hasConceptScore W2555412546C2776202225 @default.
• W2555412546 hasConceptScore W2555412546C2776262904 @default.
• W2555412546 hasConceptScore W2555412546C2777865847 @default.
• W2555412546 hasConceptScore W2555412546C2778305200 @default.
• W2555412546 hasConceptScore W2555412546C2778461978 @default.
• W2555412546 hasConceptScore W2555412546C2778729363 @default.
• W2555412546 hasConceptScore W2555412546C2778942008 @default.
• W2555412546 hasConceptScore W2555412546C2780225316 @default.
• W2555412546 hasConceptScore W2555412546C502942594 @default.
• W2555412546 hasConceptScore W2555412546C54355233 @default.
• W2555412546 hasConceptScore W2555412546C55493867 @default.
• W2555412546 hasConceptScore W2555412546C64927066 @default.
• W2555412546 hasConceptScore W2555412546C81885089 @default.
• W2555412546 hasConceptScore W2555412546C86803240 @default.
• W2555412546 hasConceptScore W2555412546C98274493 @default.
• W2555412546 hasLocation W25554125461 @default.
• W2555412546 hasOpenAccess W2555412546 @default.
• W2555412546 hasPrimaryLocation W25554125461 @default.
• W2555412546 hasRelatedWork W1968677790 @default.
• W2555412546 hasRelatedWork W2050931169 @default.
• W2555412546 hasRelatedWork W2090022532 @default.
• W2555412546 hasRelatedWork W2104364004 @default.
• W2555412546 hasRelatedWork W2139232896 @default.
• W2555412546 hasRelatedWork W2160015978 @default.
• W2555412546 hasRelatedWork W2164689318 @default.
• W2555412546 hasRelatedWork W2167510303 @default.
• W2555412546 hasRelatedWork W2555412546 @default.
• W2555412546 hasRelatedWork W2809822385 @default.
• W2555412546 isParatext "false" @default.
• W2555412546 isRetracted "false" @default.
• W2555412546 magId "2555412546" @default.
• W2555412546 workType "article" @default.